The provided source describes the development of a novel CAR T cell therapy specifically designed to treat solid tumors by targeting the tumor microenvironment rather than the cancer cells themselves. Researchers identified TREM2 as a protein highly expressed on immunosuppressive macrophages across various cancers, making it an ideal target for clearing the cells that normally protect tumors from the immune system. To increase potency, these T cells were "armored" with a synthetic biosensor that triggers the localized release of interleukin-12 (IL-12) only when the cells encounter their target. This dual approach successfully depleted suppressive macrophages and activated natural killer (NK) and T cells, leading to significant tumor shrinkage in animal models. Crucially, the use of engineered genetic circuits ensured that the powerful inflammatory cargo remained restricted to the tumor site, preventing the systemic toxicity often associated with cytokine treatments. These findings suggest a promising, antigen-independent strategy for overcoming the hostile barriers that typically limit the effectiveness of immunotherapy in solid cancers.

References:

• Yagel G, Rimini D, von Locquenghien M, et al. Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells[J]. Cancer Cell, 2026.